3 active not recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Guselkumab Dose 2: new trials by email Literature Review of Guselkumab Dose 2 trials Research Report on Guselkumab Dose 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 418 | 2022-09-13 | 2026-09-28 |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Crohn Disease | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 350 | 2022-01-19 | 2026-09-25 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Crohn's Disease | Phase 2 / Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 1409 | 2018-04-13 | 2026-09-28 |
Crohn Disease (2) · Colitis, Ulcerative (1)
Janssen Research & Development, LLC (3)
Australia (3) · Belgium (3) · Brazil (3) · Canada (3) · China (3) · Czechia (3) · France (3) · Germany (3) · Hungary (3) · Israel (3) · Japan (3) · Jordan (3) · Malaysia (3) · New Zealand (3) · Poland (3)
PMID 35134323, PMID 38104569, PMID 40113101, PMID 40357993, PMID 40684778, PMID 41544637, PMID 42065683
2023 (3), 2017 (1)